Immunosuppression

Phase 2Small molecule

NNational Heart, Lung, and Blood Institute (NHLBI)

Immunosuppression is one of 87 small molecule programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

AnemiaActive, not recruiting

PhenylketonuriaActive, not recruiting

LymphomaPhase 2

Active, not recruiting

AnemiaPhase 2

Active, not recruiting

PhenylketonuriaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Velban

EEastern Cooperative Oncology Group

Preclinical

15 2

Oncaspar

SServier

Preclinical

15 3

Immunosuppression

NNational Heart, Lung, and Blood Institute (NHLBI)

Phase 2

1 4

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 5

Tafasitamab

Incyte

Preclinical

7 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Systemic Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hematopoietic Cell Transplantation1 trial

Multicenter Study of Peritransplantation Immunosuppression for Mismatched Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

Terminated·—·Phase 2·NCT01582048·9 enrolled

Phenylketonuria1 trial

Liver Cell Transplant for Phenylketonuria

Terminated·IIra Fox·Phase 1/2·NCT01465100·1 enrolled

Lymphoma1 trial

Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas

Unknown status·AAzienda Ospedaliera San Giovanni Battista·Phase 2·NCT01786018·42 enrolled

Anemia1 trial

Induction of Stable Chimerism for Sickle Cell Anemia

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00029393

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Immunosuppression. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Immunosuppression compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Immunosuppression. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Heart, Lung, and Blood Institute (NHLBI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational Heart, Lung, and Blood Institute (NHLBI)

Immunosuppression

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hematopoietic Cell Transplantation1 trial

Phenylketonuria1 trial

Lymphoma1 trial

Anemia1 trial

References

Drug Info

Quick Facts

Related News